The Efficacy and Palatability of Developed Polyethylene Glycol-based Formula for Children With Functional Constipation
Launched by CHULALONGKORN UNIVERSITY · Apr 5, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new formula made with polyethylene glycol (PEG) to help treat children with functional constipation, which is when kids have difficulty passing stools without any physical problems causing it. The study will compare this new formula to the standard PEG treatment over an 8-week period to see which one works better and tastes better for the kids. Researchers will also check for any side effects and measure changes in rectal size during the trial.
To participate in this study, children must be between 6 months and 18 years old and have a diagnosis of functional constipation based on specific guidelines. However, some children won’t be eligible, such as those with certain medical conditions affecting their bowels or those allergic to PEG. If your child qualifies and decides to join, they can expect to try the new formula while being monitored for any side effects and improvements in their condition. This trial is not yet recruiting participants, so there will be more information available soon.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Children will be enrolled in this study when they meet 2 criteria:
- • Age from 6 months to 18 years old
- • Children are diagnosed with FC according to ROME IV criteria
- Exclusion Criteria:
- Children will be excluded from the study if they meet any of the following criteria:
- • Having an organic cause of constipation such as anorectal malformations, Hirschsprung disease, myelomeningocele, hypothyroidism, etc.
- • Suspected GI obstruction
- • Receiving medication affecting bowel movement
- • Having a history of allergy to PEG and stevia.
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Palittiya Sintusek, Ph.D.
Study Chair
Chulalongkorn University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported